Literature DB >> 7324921

Early prediction of symptomatic patent ductus arteriosus from perinatal risk factors: a discriminant analysis model.

R B Cotton, D P Lindstrom, M T Stahlman.   

Abstract

A scoring system based on discriminant analysis was devised to predict, within 24 hours after birth, whether or not a premature infant will subsequently develop a symptomatic PDA. Five risk factors including birth weight, the diagnosis of hyaline membrane disease, intrauterine growth retardation, acute perinatal stress, and treatment with distending airway pressure were reduced to a discriminant score which separated infants with symptomatic PDA from infants without symptomatic PDA. Based on this score, the likelihood that an individual infant would later develop symptomatic PDA could be expressed as a probability function. When applied prospectively, this score predicted the correct outcome of 80% of infants in a test population. This predictive model should be useful in clinical trials and other applications requiring a quantitative expression of risk for developing symptomatic ductus shunting.

Entities:  

Mesh:

Year:  1981        PMID: 7324921     DOI: 10.1111/j.1651-2227.1981.tb05775.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  11 in total

1.  Day case ligation of patent ductus arteriosus in preterm infants: a 10 year review.

Authors:  C R Satur; D R Walker; D F Dickinson
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

Review 2.  Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.

Authors:  Manoj N Malviya; Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2013-03-28

3.  Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.

Authors:  Nansi S Boghossian; Barbara T Do; Edward F Bell; John M Dagle; Jane E Brumbaugh; Barbara J Stoll; Betty R Vohr; Abhik Das; Seetha Shankaran; Pablo J Sanchez; Myra H Wyckoff; M Bethany Ball
Journal:  Early Hum Dev       Date:  2017-07-08       Impact factor: 2.079

Review 4.  Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?

Authors:  Ronald I Clyman; James Couto; Gail M Murphy
Journal:  Semin Perinatol       Date:  2012-04       Impact factor: 3.300

Review 5.  Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period.

Authors:  Jeff Reese; Alex Veldman; Lisa Shah; Megan Vucovich; Robert B Cotton
Journal:  Semin Perinatol       Date:  2010-06       Impact factor: 3.300

Review 6.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

7.  Patent ductus arteriosus in premature neonates.

Authors:  Olachi J Mezu-Ndubuisi; Ghanshyam Agarwal; Aarti Raghavan; Jennifer T Pham; Kirsten H Ohler; Akhil Maheshwari
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

8.  Indomethacin for symptomatic patent ductus arteriosus in preterm infants.

Authors:  Peter Evans; Deirdre O'Reilly; Jonathan N Flyer; Roger Soll; Souvik Mitra
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

9.  Outcome following patent ductus arteriosus ligation in premature infants: a retrospective cohort analysis.

Authors:  Lleona C L Lee; Angela Tillett; Robert Tulloh; Robert Yates; Wilf Kelsall
Journal:  BMC Pediatr       Date:  2006-05-11       Impact factor: 2.125

10.  Blood pressure changes during the first 24 hours of life and the association with the persistence of a patent ductus arteriosus and occurrence of intraventricular haemorrhage.

Authors:  Robert Boldt; Pauliina M Mäkelä; Lotta Immeli; Reijo Sund; Markus Leskinen; Päivi Luukkainen; Sture Andersson
Journal:  PLoS One       Date:  2021-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.